Post-earnings recap
Reported
Mon, Aug 11, 2025
EPS actual
$-0.95
EPS est.
$-0.89
EPS surprise
-7.22%
1-day move
-7.24%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kymera Therapeutics reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue figures and guidance updates may have added to investor concerns. The stock's decline reflects uncertainty about the company's near-term performance and strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.95 | N/A | -7.22% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious outlook, recognizing difficulties in achieving expected performance. They remain focused on strategic objectives.
Management acknowledged the challenges faced during the quarter.
They emphasized a commitment to long-term goals despite current setbacks.